Research Topics
| M WalshSummaryAffiliation: University of Calgary Country: Canada Publications
| Collaborators
|
Detail Information
Publications
Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysisMichael Walsh
Addenbrooke s Hospital, Cambridge, UK
Arthritis Care Res (Hoboken) 62:1166-73. 2010..The role of low-dose glucocorticoids (GC) in relapse prevention is controversial. We undertook a systematic review and meta-analysis to determine if GC target doses influence relapses of AAV...- Association between routine and standardized blood pressure measurements and left ventricular hypertrophy among patients on hemodialysisJaspreet Khangura
Department of Medicine, University of British Columbia, Vancouver, Canada
BMC Nephrol 11:13. 2010..We sought to determine agreement between various blood pressure measurement methods, as well as identify which method was the strongest correlate of LV hypertrophy among patients on hemodialysis... - Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitisMichael Walsh
McMaster University, Hamilton, Ontario, Canada
Arthritis Care Res (Hoboken) 63:1055-61. 2011..Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) can present with a broad spectrum of signs and symptoms. The relative effects of different manifestations on health-related quality of life (HRQOL) are unknown... 
Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H)M Walsh
Vasculitis Clinic, Box 118, Addenbrooke s Hospital, Hills Road, Cambridge, CB2 2QQ, UK
Ann Rheum Dis 67:1322-7. 2008..Humanised monoclonal anti-CD52 antibodies (alemtuzumab, CAMPATH-1H) selectively deplete lymphocytes. We present long-term follow-up results of patients with relapsing/refractory AASV treated with CAMPATH-1H...
Practice pattern variation in oral glucocorticoid therapy after the induction of response in proliferative lupus nephritisM Walsh
Department of Medicine, University of Calgary, Calgary, AB, Canada
Lupus 19:628-33. 2010..This variability likely represents clinical equipoise. A randomized trial evaluating the effect of glucocorticoid use after induction of response is warranted...- Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysisMichael Walsh
Department of Medicine, University of Calgary, Calgary, Alberta, Canada
Clin J Am Soc Nephrol 2:968-75. 2007..A systematic review and meta-analysis were performed to determine the risk for failure to induce remission of lupus nephritis in patients who were treated with mycophenolate mofetil compared with cyclophosphamide... - Targeting the B cell in vasculitisMichael Walsh
Vasculitis Clinic, Addenbrooke s Hospital, Hills Road, Box 118, Cambridge, CB2 2QQ, UK
Pediatr Nephrol 24:1267-75. 2009..Several other B-cell-directed therapies are in development and may offer rational alternatives or adjunctives to traditional treatments... - Surrogate end points in clinical trials: the case of anti-neutrophil cytoplasm antibody-associated vasculitisMichael Walsh
Vasculitis and Lupus Clinic, Department of Renal Medicine, Addenbrooke's Hospital, Cambridge, UK
J Nephrol 20:119-29. 2007 - Histopathologic features aid in predicting risk for progression of IgA nephropathyMichael Walsh
Division of Nephrology, Foothills Medical Centre, Calgary, AB, T2N 0L9, Canada
Clin J Am Soc Nephrol 5:425-30. 2010..Accurately identifying patients who are at risk for progressive disease is challenging. The extent to which histopathologic features improves prognostication is uncertain... - Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and futureM Walsh
Department of Renal Medicine, Addenbrooke s Hospital, Cambridge, United Kingdom
Kidney Int 72:676-82. 2007..Future randomized control trials and long-term follow-up studies are required to confirm the role of RTX and other B-cell targeting therapies in AASV and SLE... - Rituximab versus cyclophosphamide in ANCA-associated renal vasculitisRachel B Jones
Vasculitis and Lupus Clinic, Renal Unit, Addenbrooke s Hospital, Cambridge, United Kingdom
N Engl J Med 363:211-20. 2010..Treatment with rituximab has led to remission rates of 80 to 90% among patients with refractory ANCA-associated vasculitis and may be safer than cyclophosphamide regimens... - What is the value of mycophenolate mofetil as induction and maintenance therapy in lupus nephritis?Rachel B Jones
Renal Unit, Vasculitis and Lupus Clinic, Box 118, Addenbrooke s Hospital, Hills Road, Cambridge CB2 OQQ, UK
Curr Opin Rheumatol 21:256-61. 2009..The precise role of MMF is under ongoing evaluation. This review provides an up-to-date summary of MMF and its use as remission induction and maintenance therapy for lupus nephritis... - Health-related quality of life in a cohort of adult patients with mild hemophilia AM Walsh
The Clinical Epidemiology Unit, Department of Medicine, Memorial University of Newfoundland, St John s, NL, Canada
J Thromb Haemost 6:755-61. 2008..To compare the health-related quality of life among adult males affected with mild hemophilia A due to the same mutation (Val2016ala) to that of unaffected age and sex matched controls from the same general population... - Association between multidisciplinary care and survival for elderly patients with chronic kidney diseaseBrenda R Hemmelgarn
Department of Medicine, Community Health Schiences, University of Calgary, Calgary, Canada
J Am Soc Nephrol 18:993-9. 2007..The benefits of MDC and an assessment of their economic impact should be tested in a randomized, controlled trial... - Ascorbic acid for anemia management in hemodialysis patients: a systematic review and meta-analysisVinay Deved
Department of Medicine, University of Calgary, Calgary, Alberta, Canada
Am J Kidney Dis 54:1089-97. 2009..Ascorbic acid is believed to improve anemia in patients with end-stage renal disease, but its overall effectiveness is unclear... - The effects of nocturnal compared with conventional hemodialysis on mineral metabolism: A randomized-controlled trialMichael Walsh
Department of Medicine, University of Calgary, Alberta, Canada
Hemodial Int 14:174-81. 2010..The effects of NHD on PTH are variable. The impact of these changes on long-term cardiovascular and bone-related outcomes requires further investigation... - Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trialBruce F Culleton
Department of Medicine, University of Calgary, Calgary, Alberta, Canada
JAMA 298:1291-9. 2007..Morbidity and mortality rates in hemodialysis patients remain excessive. Alterations in the delivery of dialysis may lead to improved patient outcomes... - The effects of nocturnal hemodialysis compared to conventional hemodialysis on change in left ventricular mass: rationale and study design of a randomized controlled pilot studyMichael Walsh
Department of Medicine, University of Calgary, Calgary, Canada
BMC Nephrol 7:2. 2006..The impact of NHD on LV mass represents a clinically important outcome which will further elucidate the potential benefits of NHD and guide future clinical endpoint studies... - A systematic review of the effect of nocturnal hemodialysis on blood pressure, left ventricular hypertrophy, anemia, mineral metabolism, and health-related quality of lifeMichael Walsh
Department of Medicine, University of Calgary, Alberta, Canada
Kidney Int 67:1500-8. 2005..Before significant resources are invested in initiating nocturnal hemodialysis programs, further data on mortality and cardiovascular morbidity, preferably from randomized clinical trials, are required... - Novel predictors of overt nephropathy in subjects with type 1 diabetes. A nested case control study from the Pittsburgh Epidemiology of Diabetes Complications cohortAklilu A Yishak
Department of Medicine, University of Pittsburgh School of Medicine, and Veterans Pittsburgh Health Care System of Pittsburgh, Pittsburgh, PA 15213, USA
Nephrol Dial Transplant 21:93-100. 2006..CONCLUSION: Besides AER, the immunecomplexes and lipoprotein subclasses may provide additional information in the assessment of ON risk in type 1 diabetes... - Markers of endothelial dysfunction in the prediction of coronary artery disease in type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications StudyTina Costacou
Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA
J Diabetes Complications 19:183-93. 2005..13, 95% Cl=1.03-1.24; HRs are per standard deviation increase) but not hard CAD. Study results suggest that E-selectin may enhance CAD prediction beyond traditional risk factors or markers of oxidative stress in Type 1 diabetes...